Brief: Maia Biotechnology Receives Usan Council Approval For “Ateganosine” As Nonproprietary Name For Anticancer Agent Thio
19/03/2025 16:14
March 19 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY RECEIVES USAN COUNCIL APPROVAL FOR “ATEGANOSINE” AS NONPROPRIETARY NAME FOR ANTICANCER AGENT THIO MAIA BIOTECHNOLOGY INC - TO RETAIN NAME THIO IN CLINICAL TRIAL DESIGNATIONS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale